LOS ANGELES–(BUSINESS WIRE)—- $KAPA–Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biologi

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.